Your Article Summary
See Latest ArticlesClindamycin phosphate/tretinoin gel formulation in the treatment of acne vulgaris
Expert Opinion in Pharmacotherapy, 11/03/08
Abdel-Naser MB et al. - Clindamycin phosphate 1.2% together with tretinoin 0.025% as a gel (CTG) is a topical formulation of a fixed and stable combination approved by the FDA for the treatment of acne vulgaris in patients 12 years of age or older. The main indication of CTG is the management of moderate comedonal and mild-to-moderate papulopustular acne, an acne form which is present in more than 50% of acne patients. CTG can also be combined with systemic antiacne therapy, such as systemic isotretinoin, in nodulocystic acne.
Related Articles
Choosing the best treatments for acne
The Clinical Advisor, 11/03/09
Relevance Score: 68%
Interleukin-10 secretion from CD14+ peripheral blood mononuclear cells is downregulated in patients with acne vulgaris
British Journal of Dermatology, 10/13/09
Relevance Score: 68%
Management of acne vulgaris: an evidence-based update
Clinical and Experimental Dermatology, 11/02/09
Relevance Score: 65%
Nicotinamide inhibits Propionibacterium acnes-induced IL-8 production in keratinocytes through the NF-kB and MAPK pathways
Journal of Dermatological Science, 10/06/09
Relevance Score: 65%
Optical coherence tomography imaging of psoriasis vulgaris: correlation with histology and disease severity
Archives of Dermatological Research, 11/17/09
Relevance Score: 63%
Today in Drug Interactions...keeping you current
Receive free subspecialty "5-minute updates" via email
Cyclosporine Versus Tacrolimus in Immunosuppressive Maintenance Regimens in Renal Transplants in Brazil: Survival Analysis from 2000 to 2004
Annals of Pharmacotherapy, 12/16/09
Acetazolamide and midazolam act synergistically to inhibit neuropathic pain
Pain, 12/16/09
'Party pill' drugs - BZP and TFMPP
New Zealand Medical Journal, 12/14/09